1. Home
  2. PHR vs DBVT Comparison

PHR vs DBVT Comparison

Compare PHR & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phreesia Inc.

PHR

Phreesia Inc.

HOLD

Current Price

$9.69

Market Cap

759.0M

ML Signal

HOLD

Logo DBV Technologies S.A.

DBVT

DBV Technologies S.A.

HOLD

Current Price

$12.27

Market Cap

850.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHR
DBVT
Founded
2005
2002
Country
United States
France
Employees
N/A
90
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
759.0M
850.9M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
PHR
DBVT
Price
$9.69
$12.27
Analyst Decision
Buy
Buy
Analyst Count
18
7
Target Price
$21.18
$32.04
AVG Volume (30 Days)
600.8K
278.0K
Earning Date
05-27-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
103.92
10.26
EPS
0.08
N/A
Revenue
$480,591,000.00
$5,636,000.00
Revenue This Year
$8.43
$35.04
Revenue Next Year
$5.10
$2,360.78
P/E Ratio
$126.25
N/A
Revenue Growth
14.48
35.77
52 Week Low
$7.77
$8.86
52 Week High
$24.25
$26.19

Technical Indicators

Market Signals
Indicator
PHR
DBVT
Relative Strength Index (RSI) 36.39 N/A
Support Level $9.67 N/A
Resistance Level $10.27 N/A
Average True Range (ATR) 0.32 0.00
MACD -0.07 0.00
Stochastic Oscillator 13.44 0.00

Price Performance

Historical Comparison
PHR
DBVT

About PHR Phreesia Inc.

Phreesia Inc is a provides an integrated software, payments, and engagement platform designed to address three foundational challenges in healthcare delivery: access to care, affordability of care, and patient health outcomes. Its platform is embedded directly into provider workflows and patient interactions, enabling healthcare organizations to activate patients, streamline administrative processes, and improve financial performance across the care continuum. The group serves a diverse group of healthcare organizations, including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest, and not-for-profit and other organizations.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: